Clinical management of drug resistant tuberculosis: A comprehensive review

Authors

  • Sonal Jain Medical Writer and Reviewer
  • Arun Kumar Associate Professor, Department of Biochemistry, Manipal College of Medical Sciences, Pokhara

DOI:

https://doi.org/10.3126/ajms.v5i3.9698

Keywords:

Amikacin, Capreomycin, Direct observed therapy-short course, Drug resistance tuberculosis, Isoniazid, Kanamycin, Minimum inhibitory concentration, Multi drug resistance tuberculosis, Open reading frame, Pyrazinamide, Rifampicin

Abstract

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. This is because of development of drug resistance in tuberculosis strains, usually called as MDR/XDR-TB. Consequently, novel drugs and regimens for management of these drug resistant TB forms are emerging. Such regimens probably utilize both repurposed drugs and new chemical drugs. This article covers current concepts and recent advances in TB drug discovery and development. An updated review of the mechanisms of action and resistance of the main old and new anti-tuberculosis agents has been described. The consensus statements from RNTCP for management of MDR/XDR-TB have also been discussed.

Asian Journal of Medical Science, Volume-5(3) 2014: 1-9

DOI: http://dx.doi.org/10.3126/ajms.v5i3.9698

 

 

 

Downloads

Download data is not yet available.
Abstract
1430
PDF
1129

Downloads

Published

2014-02-24

How to Cite

Jain, S., & Kumar, A. (2014). Clinical management of drug resistant tuberculosis: A comprehensive review. Asian Journal of Medical Sciences, 5(3), 1–9. https://doi.org/10.3126/ajms.v5i3.9698

Issue

Section

Review Articles